Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2

Journal of Medical Genetics

Volumn 41, Issue 7, 2004, Pages 529-534

  Tsilchorozidou, T ^a   Menko, F H ^b   Lalloo, F ^c   Kidd, A ^e   De Silva, R ^d   Thomas, H ^d   Smith, P ^c   Malcolmson, A ^c   Dore, J ^c   Madan, K ^b   Brown, A ^e   Yovos, J G ^a   Tsaligopoulos, M ^a   Vogiatzis, N ^a   Baser, M E ^f   Wallace, A J ^c   Evans, D G R ^c  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST MARY S HOSPITAL   (United Kingdom)

^d OLDCHURCH HOSPITAL   (United Kingdom)

^e WELLINGTON HOSPITAL   (New Zealand)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHROMOSOME 22; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC SCREENING; HUMAN; KARYOTYPE 46,XX; KARYOTYPE 46,XY; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SCREENING TEST; SPINAL CORD TUMOR;

EID: 3142718879     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2003.016774     Document Type: Article

References (29)

1. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
2. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short PM, Buckler AJ, Gusella JF. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
3. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-xuan K, Demczuk S, Desmaze C, Plaugastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-21.
4. Parry DM, MacCollin M, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Boleseta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-39.
5. Evans DGR, Trueman L, Wallace A, Mason S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet 1998;35:450-5.
6. Evans DGR, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000;37:897-904.
7. Ishmael HA, Cataldi D, Begleiter ML, Pasztor LM, Dasouki MJ, Butler MG. Five new subjects with ring chromosome 22. Clin Genet 2003;63:410-14.
8. Kehrer-Sawatki H, Udart M, Krone W, Baden R, Fahsold R, Thomas G, Schmucker B, Assum G. Mutational analysis and expression studies of the neurofibromatosis type 2 (NF2) gene in a patient with ring chromosome 22 and NF2. Hum Genet 1997;100:67-74.
9. Arimani T, Hayashi N, Nagase H, Ogawa M, Nakamura Y. Multifocal meningiomas in a patient with a constitutional ring chromosome 22. J Med Genet 1986;23:178-80.
10. Duncan AMV, Partington MW, Soudek D. Neurofibromatosis in a man with a ring chromosome 22: in situ hybridization studies. Cancer Genet Cytogenet 1987;25:169-74.
11. Petrella R, Levine S, Wilmot PL, Ashar KD, Casamassima AC, Shapiro LR. Multiple meningiomas in a patient with a constitutional ring chromosome 22. Am J Med Genet 1993;47:184-6.
12. Tommerup N, Warburg M, Gieselmann V, Hansen BR, Koch J, Petersen GB. Ring chromosome 22 and neurofibromatosis. Clin Genet 1992;42:171-7.
13. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
14. Kistenmacher ML, Punnett HH. Comparative behaviour of ring chromosomes. Am J Hum Genet 1970;22:304-18.
15. Pulst SM, Rouleau GA, Marineau C, Fain P, Sieb JB. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993;43:2096-8.
16. Zucman-Rosi J, Legoix P, Thomas G. Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region. Genomics 1996;38:247-54.
17. Mohyuddin A, Neary W, Wallace A, Wu CL, Black G, Purcell S, Reid H, Ramsden RT, Read A, Evans DGR. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39:311-15.
18. Everett LA, Glaser B, Beck JK. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 1997;17:411-22.
19. Evans DGR, Wallace A, Trueman L, Wu C-L, Ramsden RT, Strachan T. Mosaicism in classical neurofibromatosis type 2: a common mechanism for sporadic disease in tumor prone syndromes? Am J Hum Genet 1998;63:727-36.
20. Kluwe L, Mautner VF, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-14.
21. Madan K. Balanced structural changes involving the human X: effect on sexual phenotype. Hum Genet 1983;63:216-21.
22. Kalz-Füller B, Sleegers E, Schwanitz G, Shubert R. Characterisation, phenotypic manifestations and X-inactivation pattern in 14 patients with X-autosome translocations. Clin Genet 1999;55:362-6.
23. Ross JL, Scott Jr C, Marttila P, Kowal K, Nass A, Papenhausen P, Abboudi J, Osterman L, Kushner H, Carter P, Ezaki M, Elder F, Wei F, Chen H, Zinn AR. Phenotypes associated with SHOX deficiency. J Clin Endocrinol Metab 2001;86:5674-80.
24. Schiller S, Spranger S, Schechinger B, Fukami M, Merker S, Drop SL, Troger J, Knoblauch H, Kunze J, Seidel J, Rappold GA. Phenotypic variation and genetic heterogeneity in Léri-Weill syndrome. Eur J Hum Genet 2000;8:54-62.
25. Arai E, Ikeuchi T, Karasawa S, Tamura A, Yamamoto K, Kida M, Ichimura K, Yuasa Y, Tonomura A. Constitutional translocation t(4,22) (q12;q12.2) associated with neurofibromatosis type 2. Am J Med Genet 1992;44:163-7.
26. Arai E, Ikeuchi T, Nakamura Y. Characterisation of the translocation breakpoint on 22q12.2 in a patient with neurofibromatosis type 2 (NF2). Hum Mol Genet 1994;3:937-9.
27. Bovie C, Holden ST, Schroer A, Smith E, Trump D, Raymond FL. Neurofibromatosis 2 in a patient with a de novo balanced reciprocal translocation 46,X,t(X;22)(p11.2;q11.2). J Med Genet 2003;40:682-4.
28. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, Saito Y, Kochi M, Kuratsu J, Saya H, Ushio Y. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001;6:441-54.
29. Evans DGR, Blair V, Strachan T, Lye RH, Ramsden RT. Variation in expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannoma. J Laryngol Otol 1995;9:830-5.